

## **Otyłość jako czynnik ryzyka chorób układu krążenia**

**prof. dr hab. med. Barbara Zahorska-Markiewicz**

- 1) Dagenais GR., Yi Q., Mann JF. i wsp.: Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. *Am. Heart J.* 2005; 149: 54-60
- 2) Despres JP. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. *Eur. J. Cardiol.* 2006; 8:suppl.B, B4-B12
- 3) EUROSPIRE II Study Group: *Eur. Heart J.* 2004; 25: 121-128
- 4) Gardner ChD., Kiazand A., S., Kim S. i wsp.: Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women. The A to Z Weight Loss Study: a randomized trial. *JAMA* 2007; 297: 969-977
- 5) Haddock C.K., Poston WS., Dill PI. i wsp.: Pharmacotherapy for obesity a quantitative analysis of four decades of published randomised clinical trials. *Int. J. Obes. Relat. Metab. Disord.* 2002; 26: 262-273
- 6) Isomaa B., Almaren P., Tuomi T. i wsp.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001; 24: 683-689
- 7) Management of Obesity in Adults: Project for European Primary Care. *Int. J. Obes.* 2004; 28, suppl. 1, 5226-5231
- 8) Obesity preventing and managing the global epidemic. Report of WHO Consultation on Obesity. Geneva 3-5 June 1997 WHO/NUT/NCD. Geneva 1998, 276 pp.
- 9) Rexrode KM., Carey VJ., Hennekens CH. i wsp.: Abdominal adiposity and coronary heart disease in women. *JAMA* 1998; 280: 1843-1848
- 10) Snow V., Barry P., Fitterman N. i wsp.: Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. *Ann. Int. Med.* 2005; 142: 525-531
- 11) Wadden TA., Berkowitz RI., Womble LG. i wsp.: Randomized trial of lifestyle modification and pharmacotherapy for obesity. *N. Eng. J. Med.* 2005; 353: 2111-2120
- 12) Wilding JPH. Treatment strategies for obesity. *Obes. Rev.* 2007; 8, suppl. 1, 137-144

- 13) Yusuf S., Hawken S., Ounpuu S i wsp.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004; 364: 937-952
- 14) Zahorska-Markiewicz B. *Nauka i praktyka w leczeniu otyłości*. Archi-Plus, Kraków 2005
- 15) Zahorska-Markiewicz B. Metabolic effects associated with adipose tissue distribution. *Advances in Medical Sciences* 2006; 51: 111-114
- 16) Zahorska-Markiewicz B. Kontrowersje wokół diet. *Endokrynol. Otyłość Zaburzenia Przemiany Materii* 2005; 1(1): 9-14.
- 17) Zahorska-Markiewicz B., Kocelak P.: Rola układu kannabinoidowego w regulacji poboru pokarmu. *Endokrynol. Otyłość Zaburzenia Przemiany Materii* 2005; 1(2): 12-17

### **Rozpowszechnienie nadwagi i otyłości w Polsce i na świecie**

dr hab. n med. Piotr Podolec, dr Grzegorz Kopec

1. Manson JE., Skerrett PJ., Greenland P., et al.: The Escalating Pandemics of Obesity and Sedentary Lifestyle. *Arch Intern Med.* 2004;164:249– 258. (1)
2. Ezzati M., Lopez AD., Rodgers A., Vander Hoorn S., Murray CJ.: Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. *Lancet* 2002; 360: 1347–60.(2)
3. WHO Monica Project (2003) MONICA Monograph and Multimedia Sourcebook: World's largest study of heart disease stroke, risk factors and population trends 1979–2002. Edited by Hugh Tunstall-Pedoe for the WHO MONICA Project. WHO: Geneva.(3)
4. Flegal KM., Carrol MD., Ogden CL., et al.: Prevalence and Trends in Obesity Among US Adults, 1999– 2000 *JAMA.* 2002;288:1723– 1727.(4)
5. Zdrojewski T., Babińska Z., Bandosz P. i wsp.: Związek nadwagi i otyłości podwyższonymi wartościami ciśnienia tętniczego w badaniach reprezentatywnych grup dorosłych Polaków w 1997 i 2002 roku. (NATPOL II, NATPOL III). *Medycyna Metaboliczna* 2002; 4, 32.
6. Biela U., Pająk A., Kaczmarczyk-Chałas K. i wsp.: Częstość występowania nadwagi i otyłości u kobiet i mężczyzn w wieku 20– 74 lat. Wyniki programu WOBASZ. *Kardiologia Polska* 2005;63:6(supl. 4).
7. Podolec P, Kopec G. Rozpowszechnienie nadwagi i otyłości w populacji dorosłych Polaków – wyniki badania POLSCREEN. W: Cieśliński A, Pająk A, Podolec P, Rynkiewicz A (red.) *Ogólnopolski Program Prewencji Choroby Wieńcowej POLSCREEN*. Termedia, Poznań 2006.

Otyłość i zespół metaboliczny u dzieci i młodzieży – epidemiologia, klasyfikacja i leczenie.

**Prof. dr hab. Ewa Małecka-Tendera,**

1. 3 International Obesity Task Force, European Union Platform Briefing Paper. Bruksela, 15 marca 2005
2. Oblacińska A., Wrocławska M., Woynarowska B.: Częstość występowania nadwagi i otyłości w populacji w wieku szkolnym w Polsce oraz opieka zdrowotna nad uczniami z tymi zaburzeniami. *Ped. Pol.*, 1997; 72: 241–245
3. Małecka-Tendera E., Klimek K., Matusik P. i wsp., on behalf of the Polish Childhood Obesity Study Group.: Obesity and overweight prevalence in Polish 7-to 9-year-old children. *Obes. Res.*, 2005; 13: 964–968
4. Palczewska I., Szilagyi-Pagowska I.: Ocena rozwoju somatycznego dzieci i młodzieży. *Med. Prakt. Ped.* 2002; 3: 1–7
5. Matusik P., Małecka-Tendera E., Nowak A.: Metody stosowane w praktyce pediatrycznej do oceny stopnia odżywienia dzieci. *Endokrynologia, Otyłość i Zaburzenia Przemiany Materii*, 2005; 1: 6–11
6. Ford E., Giles W., Mokdad A.: Increasing prevalence of the metabolic syndrome among U.S. adults. *Diabetes Care.* 2004; 27: 2444
7. Firek-Pędras M., Małecka-Tendera E., Klimek K., Zachurzok-Buczyńska A.: Wpływ rozmieszczenia tkanki tłuszczowej na zaburzenia metaboliczne u dzieci i młodzieży z otyłością prostą. *Endokrynologia, Diabetologia i Choroby Przemiany Materii Wiekowego*, 2006; 12: 19–24
8. Skowrońska B., Fichna P., Stankiewicz W., Majewska K.: Pediatric prevention of metabolic syndrome and type 2 diabetes in obese children and adolescents – when to start? *Pediatr. Diabetes*, 2005; 6 (supl. 3): 28

### **OTYŁOŚĆ DZIECI I MŁODZIEŻY – przyczyny, sposoby oceny i metody zapobiegania.**

**Dr hab. n. med. Anna Obuchowicz**

1. International Obesity Task Force. Childhood Report. *IASO Newsletter*, 2004; 6: 10–11
2. Obuchowicz A.: Epidemiologia nadwagi i otyłości – narastającego problemu zdrowotnego w populacji dzieci i młodzieży. *Endokrynologia, Otyłość i Zaburzenia Przemiany Materii*. 2005; 1(3): 9–12

3. Weker H.: Badania nad powiązaniem czynnika żywieniowego z otyłością prostą u dzieci. *Medycyna Wieku Rozwojowego*. 2006; 10 (1): 1–191
4. Socha P., Socha J.: Otyłość prosta i możliwości jej zapobiegania. *Pediatr. Pol.*, 2003; 78: 7–12
5. Ebbeling C.B., Pawlak D.B., Ludwig D.S.: Childhood obesity: public-health crisis, common sense cure. *Lancet*, 2002; 360: 473–482
6. Manson J.E., Skerrett P.J., Greenland Ph., VanItallie T.B.: The escalating pandemics of obesity and sedentary lifestyle. *Arch. Intern. Med.*, 2004; 164: 249–258.
7. Palczewska I., Niedźwiecka Z.: Wskaźniki rozwoju somatycznego dzieci i młodzieży warszawskiej. *Medycyna Wieku Rozwojowego*, 2001; 5 (2): supl. 1.

### **Otyłość istotnym czynnikiem ryzyka w medycynie okolooperacyjnej**

Prof. dr hab. med. Janusz Andres

1. Van Aken H., Reinhart K., Zimpfer M., Velte T. red.: *Intensivmedizin*. Georg Thieme Verlag, 2., Auflage, 2007: 484
2. Ronald D. Miller red.: *Miller's Anesthesia Sixth Edition*. ELSEVIER, 2005: 1028
3. Roizen M. F.: RealAge and you: are you as young as you can be an overview of prevention for preoperative clinics. *Book of Proceedings 10<sup>th</sup> International Congress of Cardiothoracic and Vascular Anesthesia*, Praga, 2006, [www.realage.com](http://www.realage.com)

### **Nadwaga i otyłość z punktu widzenia profilaktyki i leczenia nadciśnienia tętniczego**

prof. dr hab. med. Danuta Pupek - Musialik

1. Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. *Hypertension*. 2005; 45(6): 1035-41
2. Appel J., Brands W., Daniels S., Karanja N., Elmer P., Sacks F., American Heart Association. Dietary approaches to prevent and treat hypertension: A Scientific Statement from the American Heart Association. *Hypertension* 2006; 47: 296-308
3. Chiang B., Perlman L., Epstein F.: Overweight and hypertension. A review. *Circulation* 1969; 39: 403–421.
4. Faber A.: Readings of blood pressure of 1000 healthy individuals age 20-25 years. An antropometric study. *Scand. Arch. Physiol.* 1924; 45: 189–203.
5. Kopeć E., Widerska K., Krzyżanowska-Świniarska B., Dziura J., Pilarska K. Wpływ kompleksowego, ambulatoryjnego nefarmakologicznego leczenia otyłości na ciśnienie tetnicze w 24-godzinnej rejestracji. *Nadciśnienie tętnicze* 2004; 8: 159-167
6. Leiter LA, Abbott D, Campbell NR, Mendelson R, Ogilvie RI, Chockalingam A. Lifestyle modifications to prevent and control hypertension. 2. Recommendations on obesity and weight loss. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. *CMAJ*. 1999;160(9 Suppl): 7-12

7. Sharma A., Engeli S.: Managing big issues on lean evidence: treating obesity hypertension. *Nephrol. Dial. Transplant.* 2002; 17: 353–355.
8. Sharma A., Pischon T., Engeli S. i wsp.: Choice of drug treatment for obesity-related hypertension: where is the evidence? *J. Hypertens.* 2001; 19: 667–674.
9. Sharma A., Pischon T., Hardt S. i wsp.: Hypothesis: -adrenergic receptor blockers and weight gain – a systematic analysis. *Hypertension* 2001; 37: 250–254.
10. Siani A., Cappuccio F., Barba G. i wsp.: The relationship of waist circumference to blood pressure: the Olivetti Heart Study. *Am. J. Hypertens.* 2002; 15: 780–786.
11. Staessen J., Fagard R., Lijnen P., Amery A. Body weight, sodium intake and blood pressure. *J Hypertens* 1989; 7(Suppl 1): 1923
12. Stamler R., Stamler J., Riedlinger W. i wsp.: Weight and blood pressure. Findings in hypertension screening of 1 million Americans. *JAMA* 1978; 240: 1607–1610.
13. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. *JAMA* 2003; 289: 2560–2571.
14. The World Health Report 2002. Reducing Risks, Promoting Health, Life, Geneva 2002.

## **Zespół bezdechu sennego a choroby układu krążenia**

**prof. dr hab. med. Krzysztof Narkiewicz**

1. Young T, Palta M, Dempsey J, Skarrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med* 1993; 328: 1230-1235
2. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. *N Engl J Med* 2000; 342: 1378-1784.
3. Haas DC, Foster GL, Nieto FJ, Redline S, Resnick HE, Robbins JA, Young T, Pickering TG. Age-dependent associations between sleep-disordered breathing and hypertension: importance of discriminating between systolic/diastolic hypertension and isolated systolic hypertension in the Sleep Heart Health Study. *Circulation.* 2005; 111: 614 - 621.
4. Guilleminault C, Connolly SJ, Winkle RA. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. *Am. J. Cardiol.* 1983; 52: 490 - 494.
5. Gami AS, Pressman G, Caples SM et al. Association of Atrial Fibrillation and Obstructive Sleep Apnea. *Circulation* 2004; 110: 364 - 367.
6. Mehra R., Benjamin E.J., Sahar E. et al. Association of Nocturnal Arrhythmias with Sleep-disordered Breathing. The Sleep Heart Health Study. *Am. J. Respir. Crit. Care Med.* 2006; 173: 910-916.
7. Gami AS, Howard DE, Olson EJ, Somers VK. Day-night pattern of sudden death in obstructive sleep apnea. *N Engl J Med.* 2005; 352: 1206-14.
8. Hung J, Whitford EG, Parsons RW, Hillman DR. Association of sleep apnoea with myocardial infarction in men. *Lancet* 1990; 336: 261 - 264.
9. Moe T, Rabben T, Wiklund U, Franklin KA, Eriksson P. Sleep-disordered breathing in women: occurrence and association with coronary artery disease. *Am J Med* 1996; 101: 251–256.
10. Peled N, Abinader EG, Pillar G, Sharif D, Lavie P. Nocturnal Ischemic Events in Patients With Obstructive Sleep Apnea Syndrome and Ischemic Heart Disease

Effects of Continuous Positive Air Pressure Treatment. *J Am Coll Cardiol* 1999; 34: 1744-1749.

11. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Nieto FJ, O'Connor GT, Boland LL, Schwartz JE, Samet JM. Sleep-disordered Breathing and Cardiovascular Disease. Cross-sectional Results of the Sleep Heart Health Study. *Am J Respir Crit Care Med* 2001; 163: 19 - 25.
12. Peker Y, Kraiczi H, Hedner J, Löth S, Johansson A, Bende M. An independent association between obstructive sleep apnoea and coronary artery disease. *Eur Respir J* 1999; 13: 179-184.
13. Peker Y, Hedner J, Kraiczi H, Löth S. Respiratory disturbance index - an independent predictor of mortality in coronary artery disease. *Am J Respir Crit Care Med* 2000; 162: 81-86.
14. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Nieto FJ, O'Connor GT, Boland LL, Schwartz JE, Samet JM. Sleep-disordered Breathing and Cardiovascular Disease. Cross-sectional Results of the Sleep Heart Health Study. *Am J Respir Crit Care Med* 2001; 163: 19 - 25.
15. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, Leung RS, Bradley TD. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. *J Hypertens* 2001; 19: 2271-2277.
16. Ali NJ, Davies RJ, Fleetham JA, Stradling JR. The acute effects of continuous positive airway pressure and oxygen administration on blood pressure during obstructive sleep apnea. *Chest* 1992; 101: 1526-32 (Streszczenie).
17. Wilcox I, Grunstein RR, Hedner JA, Doyle J, Collins FL, Fletcher PJ, Kelly DT, Sullivan CE. Effect of nasal continuous positive airway pressure during sleep on 24-hour blood pressure in obstructive sleep apnea. *Sleep* 1993; 16: 539-544.
18. Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. *Am J Respir Crit Care Med* 2001; 163: 344-348.

## **Otyłość a depresja**

**dr hab. med. Dominika Dudek**

1. Kępiński A: Melancholia. PZWL, Warszawa, 1974
2. Mahli GS, Bridges PK: Postępowanie w depresji. Urban & Partner, Wrocław, 2001
3. Puzyński S: Depresje i zaburzenia afektywne. Wydawnictw Lekarskie PZWL, Warszawa, 2005
4. Rzewuska M (red): Leczenie zaburzeń psychicznych. Wydawnictwo Lekarskie PZWL, Warszawa, 2003

## **Farmakoterapia otyłości w praktyce klinicznej**

**dr n. med. Katarzyna Cyganek**

**dr hab n. med. Maciej Małecki**

1. Raport of the WHO consultation: Obesity: preventing and managing the global epidemic. World Health Organ Tech Rep Ser 2000, 894: 1 - 253.
2. National Institutes of Health, National Heart, lung and Blood Institute. Obesity Education Initiative: Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The Evidence Report: US Department of Health and Human Services, Public Health Service, NIH, HHLBI. Bethesda, Md; June 1998.
3. Pi-Sunyer X.: The role of Weight Loss in Improving Metabolic Outcomes. Clinical Update, Medscape 2002, 3: 1 – 15.
4. Zdrojewski T., Babinska Z., Bandosz P., Kakol M., Szpakowski P., Gnacińska M., Krupa – Wojciechowska B., Wyrzykowski B.: Związek nadwagi i otyłości z podwyższonymi wartościami ciśnienia tętniczego w badaniach reprezentatywnych grup dorosłych Polaków w 1997 i 2002r (NATPOL II, NATPOL III). Medycyna Metaboliczna 2002, 4(Suppl.): 32.
5. Kahn B., Flier J.: Obesity and insulin resistance. J Clin. Invest. 2000, 106: 473 – 481.
6. Field A., Coakley E., Spadano J., Laird N., Dietz W., Rimm E., Colditz G.: Impact of overweight on the risk of developing common chronic disease during 10-year period. Arch Intern Med. 2001, 161: 1581 - 1586.
7. Calle E., Rodriguez C., Walker-Thurmond K., Thun M.: Overweight, obesity and mortality from cancer in prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348(17): 1625 - 1638.
8. McAuley K., Williams S., Mann J., Goulding A., Chisholm A., Wilson N., Story G., McLay R., Harper M., Jones L.: Intensive lifestyle changes are necessary to improve insulin sensitivity: a randomised controlled trial. Diabetes Care 2002, 25: 445 - 452.

9. Uusitupa M., Lindi V., Louheranta A., Salopuro T., Lindström J., Tuomilehto J., for the Finnish Diabetes Prevention Study Group: Long-Term Improvement in Insulin Sensitivity by Changing Lifestyles of People with Impaired Glucose Tolerance 4-Year Results From the Finnish Diabetes Prevention Study. *Diabetes* 2003, 52: 2532 – 2538.
10. Lindström J., Louheranta A., Mannelin M., Rastas M., Salminen V., Eriksson J., Uusitupa M., Tuomilehto J., for the Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS). Lifestyle intervention and 3-year results on diet and physical activity. *Diabetes Care* 2003, 26: 3230 – 3236.
11. Van der Bruggen M., Bos G., Bemelmans W., Hoogenveen R., Vijgen S., Baan C.: Lifestyle Interventions Are Cost-Effective in People With Different Levels of Diabetes Risk. Results from a modelling study. *Diabetes Care* 2007, 30: 128 – 134.
12. Tuomilehto J., Lindström J., Eriksson J., at all: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N.Engl. J Med.*, 2001, 344: 134 – 1350.
13. Wing R., Goldstein M., Acton K., Birch L., Jakicic J., Sallis J., Smith - West D., Jeffery R., Surwit R.: Behavioural Science Research in Diabetes. Lifestyle changes related to obesity, eating behavioural and physical activity. *Diabetes Care* 2001, 24: 117 - 123.
14. 2. Gokcel A., Karakose H., Erotreer E, Tanaci N., Tutuncu N., Guvener N.: Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. *Diabetes Care* 2001, 24: 1957 - 1960.
15. 3. Finer N., Bloom S., Frost G., Banks L., Griffiths J.: Sibutramine for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. *Diabetes Obes Metab* 2000, 2: 105 - 112.
16. 4. James W., Astrup A., Finer N., Hilsted J., Kopelman P., Rossner S, Saris W., Van Gaal L.: Effect of sibutramine on weight maintains after weight loss: a randomised trial.

- STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. *Lancet* 2000, 356: 2119 – 2125.
17. 5. Redmon B., Reck K., Raatz S., Swanson J., Kwong C., Ji H., Thomas W., Bantle J.: Two-Year Outcome of a Combination of Weight Loss Therapies for Type 2 Diabetes. *Diabetes Care*. 2005, 28 (6): 1311-1315.
  18. Miles J., Leiter L., Hollander P., Wadden T., Anderson J., Doyle M., Foreyt J., Aronne L., Klein S.: Effect of Orlistat in Overweight and Obese Patients With Type 2 Diabetes Treated With Metformin. *Diabetes Care* 2002, 25: 1123 – 1128.
  19. Kelley D., Kuller L., Mkolanis T., Harper P., Mancino J., Kalhan S.: Effects of Moderate Weight Loss and Orlistat on Insulin Resistance, Regional Adiposity, and Fatty Acids in Type 2 Diabetes. *Diabetes Care* 2004, 27: 33 – 44.
  20. Torgerson J., Hauptman J., Boldrin M., Oström L: XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care* 2004, 27: 155 – 161.
  21. Lamotte M., Annemans L., Lefever A., Nechelpu M., Masure J.: A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patient. *Diabetes Care* 2001, 25: 303 – 308.
  22. Richelsen B., Tonstad S., Rössner S., Toubro S., Niskanen L., Madsbad S., Mustajoki P., Rissanen A.: Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients. *Diabetes Care* 2007, 30: 27 – 32.
  23. Cota D., Marcisano G., Vicannati V., Stalla G., Pasqualli R., Pagotto U.: Endogenous cannabinoid system as modulator of food intake. *Int J Obes* 2003, 27: 189 – 301.

24. Cota D., Marcisano G., Tschop M.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. *Int J Obes* 2003, 112: 423 – 431.
25. Van Gaal L., Rissanen A., Scheen A., Ziegler O., Rossner S.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. *Lancet* 2005, 365: 1389-1397.
26. Pi-Sunyer F., Aronne L., Heshmati H., Devin J., Rosenstock J.: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. *JAMA*. 2006; 295(7):761-75 (ISSN: 1538-3598).
27. Scheen A., Finer N., Hollander P., Jensen M., Van Gaal L., RIO-Diabetes Study Group: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. *Lancet* 2006, 368(9548): 1632 – 1634.
28. Diabetes Prevention Program Research Group. Reduction in the incidents of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002, 346: 393 - 403.
29. Pender C., Goldfine I., Tanner C., Pories W., MacDonald K., Have P., Houmard J., Youngren J.: Muscle insulin receptor concentrations in obese patients post bariatric surgery: relationship to hyperinsulinemia. *Intern J of Obesity* 2004, 28: 363 – 369.
30. Dixon J., O'brien J.: Health Outcomes of Severely Obese Type 2 Diabetic Subjects 1 Year After Laparoscopic Adjustable Gastric Banding. *Diabetes Care* 2002, 25: 358 – 363.
31. Morabito A., Doldi S.: Laparoscopic Gastric Banding Prevents Type 2 Diabetes and Arterial Hypertension and Induces Their Remission in Morbid Obesity A 4-year case-controlled study. *Diabetes Care* 2005 28: 2703 – 2709.

32. le Roux C., Aylwin S., Batterham R., Borg C., Coyle F., Prasad V., Shurey S., Ghatei M., Patel A., Bloom S.: Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters. *Ann Surg.* 2006, 243(1): 108 – 114.

### **Znaczenie aktywności fizycznej w profilaktyce i leczeniu nadwagi i otyłości.**

#### **Prof. dr hab. med. Wojciech Drygas**

1. Biela U, Pajak A, Kaczmarczyk-Chałas K. i wsp. : Częstość występowania nadwagi i otyłości u mężczyzn w wieku 20-74 lat. Wyniki programu WOBASZ. *Kardiologia Polska* 2005, 63, Supl IV, 632-636
2. Drygas W : Czy „siedzący” tryb życia nadal stanowi zagrożenie dla zdrowia społeczeństwa polskiego ? *Medycyna Sportowa* 2006, 22, 111-116
3. Drygas W, Kwaśniewska M, Szcześniewska D i WSP : Ocena poziomu aktywności fizycznej dorosłej populacji Polski. Wyniki programu WOBASZ. *Kardiologia Polska* 2005, 63, Supl IV, 636-641
4. Jakicic JM, Otto AD : Treatment and prevention of obesity : what is the role of exercise ? *Nutrition Reviews* 2006, 64, S57-61
5. Kay SJ, Fiartrone Singh MA : The influence of physical activity on abdominal fat : a systematic review of literature. *Obesity Reviews* 2006, 7, 183-200
6. Shaw K, Gennat H, O'Rourke P, Del Mar C : Exercise for overweight and obesity . *Cochrane Database Systematic Reviews* 2006, 18 , CD003817

#### **Diety odchudzające – rodzaje i bezpieczeństwo**

Prof. dr hab. n. med. Longina Kłosiewicz-Latoszek

1. Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults – the Evidence Report. National Institutes of Health. *Obesity Reviews*. 1998, 6, 51 S-209 S.
2. Klein S., Burke L.E., Bray G.A., et. al.: Clinical implications of obesity with specific focus on cardiovascular disease: A statement for professionals from American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. *Circulation*, 2004, 110, 2952-67.
3. Wadden T.A., Butryn M.L., Wilson C.: Lifestyle modification for the management of obesity. *Gastroenterology*, 2007, 132 2226-38.
4. Perri M.G., Corsica J.A.: Improving the maintenance of weight lost in behavioral treatment obesity. In: Wadden T.A., Stunkard A.J. (Eds.), *Handbook of obesity treatment*. New York, Guilford Press, 2002, 357-379.

5. Tsai A.G., Wadden T.A.: The evolution of very-low-calorie diets: an update and meta-analysis. *Obesity*, 2006, 14, 1283-93.
6. Wadden T.A., Foster G.D., Letizia K.A.: One-year behavioral treatment of obesity: comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy. *J. Consult. Clin. Psychol.* 1994, 62, 165-171.
7. Białkowska M.: Leczenie otyłości. w: *Otyłość. Zapobieganie i leczenie.* red. M. Jarosz, L. Kłosiewicz-Latoszek, PZWL, 2006, 60-90.
8. Kamrath R.O., Plummer L.J., Sadur C.N. et. al.: Cholelithiasis in patients treated with a very-low-calorie-diet. *Am. J. Clin. Nutr.*, 1992, 56, 255 S – 257 S.
9. Grzybek A., Kłosiewicz-Latoszek L., Targosz U.: Changes in the intake of vitamins and minerals by men and women with hyperlipidemia and overweight during dietetic treatment. *Eur. J. Clin. Nutr.*, 2002, 56 (12), 1162-8.
10. Ludwig D.S., Majzoub J.A., Al-Zahrani A.: High-glycemic index foods, overeating, and obesity. *Pediatrics*, 1999, 103, 26-32.
11. De Rougemont A., Normand S., Nazare J.A., et. al. : Beneficial effects of a 5-week low glycaemic index regimen on weight control and cardiovascular risk factors in overweight nondiabetic subjects. *Br. J. Nutr.*, 2007, Jul 9, 1-11.
12. Murakami K., Sasaki S., Okubo H., et. al.: Dietary fiber intake, dietary glycemic index and load, and body mass index: a cross-sectional study of 3931 Japanese women aged 18-20 years. *Eur. J. Clin. Nutr.* 2007, advance online publication, 24 January.
13. Mc Millan-Price J., Petocz P., Atkinson F., et. al. : Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomised controlled trial. *Arch. Intern. Med.*, 2006, 166, 1466-75.
14. Kłosiewicz-Latoszek L.: Czy istnieją „cudowne diety i leki”? w: *Otyłość. Zapobieganie i leczenie.* red. M. Jarosz, L. Kłosiewicz-Latoszek, PZWL, 2006, 132-138.
15. Atkins R.C.: *Dr Atkins' new diet revolution.* New York: Avon Books, 1998.
16. Szostak W.B., Białkowska M., Cichońska A., Kłosiewicz-Latoszek L., Cybulska B.: Ocena zasadności „diety optymalnej” w profilaktyce metabolicznych chorób cywilizacyjnych, wyd. IZZ, nr 106, Warszawa, 2004
17. Kłosiewicz-Latoszek L.: Efekt diet niskotłuszczowych i niskowęglowodanych. *Żyw. Człow. Metab.*, 2004, 41 (4), 344-352
18. Nordmann A.J., Nordmann A., Briel M., et. al.: Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. *Arch. Intern. Med.* 2006, 166: 285-293.
19. Fleming R.M.: The effect of high-, moderate, and low-fat diets on weight loss and cardiovascular disease risk factors. *Prev. Cardiol.* 2002, 5, 110-118.
20. Trichopoulos A., Psaltopoulou T., Orfanos P., et. al. : low-carbohydrate-high-protein diet and long-term survival in a general population cohort. *Eur. J. Clin. Nutr.*, 2007, 61, 575-81.

## **Rola psychoterapii w modyfikacji zachowań u osób z nadwagą**

**mgr Monika Bąk - Sosnowska**

- 1 Bąk – Sosnowska M., Zahorska – Markiewicz B. (2003). Aspekty psychologiczne grupowego leczenia otyłości. *Medycyna Metaboliczna*, t. 8 (3), 73 – 7.
- 2 Bąk-Sosnowska M., Zahorska – Markiewicz B., Bargiel- Matusiewicz K. (2004). Psychologiczny program wspomagający redukcję masy ciała jako istotny element

wtórnej prewencji otyłości. *Wiadomości Lekarskie, t. 57 supl.1: Międzynarodowa Konferencja Naukowa "Profilaktyka w Medycynie"*. Katowice 24-25.09.2004, s.14-16.

3            Bąk-Sosnowska M. (2005). Psychologiczne uwarunkowania niepowodzeń w odchudzaniu. *Annales Academiae Medicae Silesiensis*, 59 (4), s. 324 - 327.

4            **Bąk-Sosnowska M., Mandal E., Zahorska-Markiewicz B. (2006). Związek nieadekwatnego wyobrażenia własnego ciała z nadwagą u kobiet. *Annales Academiae Medicae Silesiensis*, 60 (5), 385 – 389.**

5            Berkel L. A., Carlos-Poston W. S., Reeves R. S., Forey J.P. (2005). Behavioral interventions for obesity. *Journal of the American Dietetic Association*, 105 (5 Pt 2), 35 – 43.

6            Besteghi L., Di Domizio S., Sartini A., Pasqui F., Baraldi L., Forlani G., Melchionda N., Marchesini G., Natale S., Manini R., Chierici S. (2002). Effects of cognitive-behavioural therapy on health-related quality of life in obese subjects with and without binge eating disorder. *International Journal of Obesity*, 26 (9), 1261 – 1267.

7            Brantley P., Myers V., Roy H. (2005). Environmental and lifestyle influences on obesity. *The Journal of the Louisiana State Medical Society*, 157 (spec. 1), 19 – 27.

8            Fairburn Ch., Cooper Z. (1996). New perspectives on dietary and behavioural treatments for obesity. *International Journal of Obesity*, 20 (supl.1), 9 - 13.

9            Finch E., Linde J., Jeffery R., Rothman A., King C., Levy R. (2005). The effects of outcome expectations and satisfaction on weight loss and maintenance: correlational and experimental analyses--a randomized trial. *Health Psychology*, 24 (6), 608 - 16.

10            Golay A, Buclin S, Ybarra J, Toti F, Pichard C, Picco N, de Tonnac N, Allaz A. (2004). New interdisciplinary cognitive-behavioural-nutritional approach to obesity treatment: a 5-year follow-up study. *Eating and Weight Disorders*, 9 (1), 29 – 34.

11            Hayaki J., Brownell K. (1996). Behaviour change in practice: group approaches. *International Journal of Obesity*, 20 (supl. 1), 27 – 30.

12            Ogińska – Bulik N. (2004). *Psychologia nadmiernego jedzenia. Przyczyny, konsekwencje, sposoby zmiany*. Łódź: Wydawnictwo Uniwersytetu Łódzkiego.

13            van Hout G., van Oudheusden I., van Heck G. (2004). Psychological profile of the morbidly obese. *Journal of Human Nutrition*, 14 (5), 579 – 88.

14            Verheijden M., Bakx J., van Weel C., Koelen M., van Staveren W. (2005). Role of social support in lifestyle-focused weight management interventions. *European Journal of Clinical Nutrition*, 59 (supl 1), 179 – 186.

- 15                    Wing R., Phelan S. (2005). Long-term weight loss maintenance. The *American Journal of Clinical Nutrition*, 82 (supl 1), 222 – 225.
- 16                    Zahorska – Markiewicz B. (2004). Aktualna strategia leczenia otyłości. *Kardiologia w praktyce*, 3, 8 – 13.
- 17                    Zahorska – Markiewicz B. (2005). *Nauka i praktyka w leczeniu otyłości*. Kraków: ArchiPlus.
- 18                    Zubrzycka E. (2001). *Schudnąć bez diety*. Gdańsk: GWP.

### **Chirurgiczne leczenie otyłości**

**Dr hab. n.med. Mariusz Wyleżół**

1. Fried M, Hainer V, Basdevant A, Buchwald H, Deitel M, Finer N, Greve JW, Horber F, Mathus-Vliegen E, Scopinaro N, Steffen R, Tsigos C, Weiner R, Widhalm K. Inter-disciplinary European guidelines on surgery of severe obesity. *Obes Surg* 2007; 17: 260-70.
2. Żwirska-Korczala Krystyna, Wyleżół Mariusz  
Surgical treatment of obesity.  
W: The various types and treatment for obesity.  
Ed.: I. Harsch. New York: Nova Sci. Publ. 2005, s. 285-306.
3. Stanowski Edward, Wyleżół Mariusz, Paśnik Krzysztof  
Laparoskopia w chirurgii bariatrycznej w Polsce - stan aktualny.  
*Wideochirurgia i inne techniki małoinwazyjne* 2007; 2: 18-23.
4. Wyleżół Mariusz, Sosada Krystyn, Wiewióra Maciej, Piecuch Jerzy, Żurawiński Wojciech, Sitkiewicz Tomasz, Gluck Marek  
Migracja tasiemki u chorej po plastyce żołądka jako wynik leczenia nietolerancji restrykcji poprzez częściowe wewnętrzne nacięcie ściany żołądka.  
*Wideochirurgia i inne techniki małoinwazyjne* 2007; 2: 39-41.